Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Gemma Medcalf

- PMLiVE

Keytruda closes in on Opdivo’s lead in Hodgkin lymphoma

KEYNOTE-087 trial shows an overall response rate of 69 percent

What does the Five Year Forward View mean for pharma?

Sue Thomas and Paul Midgley, of Wilmington Healthcare, assess how the Five Year Forward View (5YFV) is changing the NHS and how pharma can get involved in redesigning NHS services.

Wilmington Healthcare

- PMLiVE

New Jardiance label could boost sales by $1.7bn, says analyst

Diabetes treatment can reduce the risk of cardiovascular death in type 2 patients

Walgreens to show drug efficacy reports from PatientsLikeMe

Will also show alternative choices of medication

- PMLiVE

Aurora appoints Siân Hurst as managing director

Healthcare agency’s founders Neil Crump and Claire Eldridge move to CEO roles

- PMLiVE

Pfizer’s SMO inhibitor boosts survival in blood cancer trial

Glasdegib first to show benefit in patients with AML or MDS

- PMLiVE

Novartis plans filing for lead CAR-T therapy early next year

Shows complete remission for 82 percent of paediatric and young adult B-cell ALL patients

AstraZeneca AZ

AZ signs $1bn deal with Bicycle Therapeutics

Eyes broad range of applications for the firm’s peptide technology

- PMLiVE

AstraZeneca’s John Rex joins UK biotech F2G

Takes up the role of chief medical officer at the UK company

Healthcare in the Digital Age

Healthcare is changing. By understanding the needs of the physicians, and using innovative channels to make meaningful connections, pharma can ensure it continues to enjoy a mutually beneficial relationship.

M3 (EU)

M3 announces further expansion into Europe and Latin America with the acquisition of Vidal Group

M3 is strengthening and growing its global operations with the acquisition of Vidal Group, a trusted provider of prescribing information and clinical decision support services to doctors and other HCPs...

M3 (EU)

- PMLiVE

NICE green lights Keytruda for second-line lung cancer

Merck & Co's oncology treatment backed in draft guidance for NSCLC

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links